Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNF2105 in Advanced Solid Tumors
NCT07661797Phase 1Not yet recruiting
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Jun 2026
- Primary completion
- Jun 2028
01
Overview
Phase 1, open-label, single-arm trial of LNF2105 in solid tumor, sponsored by Shandong New Time Pharmaceutical. Primary endpoints: Safety and Tolerability at 24 months, Dose Limiting Toxicities at 28 days and 2 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
LNF2105
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07661797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07661797.